Phaseline

Targets › HTR1A

HTR1A (5-hydroxytryptamine receptor 1A): drug programs, companies and trials

19 programs from 16 companies in 36 trials: 10 Phase 3, 10 Phase 1, 8 Phase 4, 8 Phase 2; Psychiatry, Neurology, Oncology; next expected readout Dec 2026.

G protein-coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. (UniProt, P08908)

Open in Phaseline: the race on HTR1A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
VA Office of Research and DevelopmentBuspirone
Serotonin 1a (5-HT1a) receptor partial agonist
HTR1APhase 4Sleep Disordered BreathingDec 2026
Valenta Pharm JSCVespireit
5-HT1A receptor agonist
HTR1APhase 4VertigoDec 2026
Massachusetts General HospitalBuspirone
Serotonin 1a (5-HT1a) receptor partial agonist
HTR1APhase 4Depression; AnxietyJul 2028
Northwell Healtharipiprazole
Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist
DRD2, HTR1A, HTR2APhase 4Psychosis; Acute; Schizophenia DisorderDec 2029
Massachusetts General HospitalAripiprazole
Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist
DRD2, HTR1A, HTR2APhase 4Bipolar I DisorderFeb 2030
University of California, Los AngelesCBD 20 mg
GABA-A receptor; anion channel positive allosteric modulator
HTR1A, GABRA1, GABRB2, GABRG2, GABRB3, GABRA4, SLC1A2, SLC1A3Phase 3Spinocerebellar Ataxias; Non-healing Wound; Sleep Apnea, Obstructive; Cervical Spinal Cord Injury …Dec 2026
Shanghai Mental Health CenterAripiprazole
Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist
DRD2, HTR1A, HTR2APhase 3Treatment-resistant Schizophrenia; Obsessive-Compulsive DisorderJun 2027
OtsukaBrexpiprazole
Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist
DRD2, HTR1A, HTR2APhase 3Acute SchizophreniaSep 2027
Vanda PharmaceuticalsMilsaperidone
5-HT1A receptor partial agonist
HTR1APhase 3Major Depressive Disorder (MDD)Mar 2028
OtsukaUlotaront (SEP-363856)
Serotonin 1a (5-HT1a) receptor agonist; Trace amine-associated receptor 1 agonist
HTR1A, TAAR1Phase 3Schizophrenia; Generalized Anxiety DisorderOct 2028
TakedaVortioxetine
Serotonin 1a (5-HT1a) receptor agonist; Serotonin transporter inhibitor; Serotonin 3a (5-HT3a) receptor antagonist
HTR1A, SLC6A4, HTR3APhase 3Major Depressive Disorder; Glioblastoma; DepressionSep 2029
University of Maryland, BaltimoreBuspirone
Serotonin 1a (5-HT1a) receptor partial agonist
HTR1APhase 2Opioid Use DisorderJan 2027
Spaulding Rehabilitation HospitalBuspirone Hydrochloride
Serotonin 1a (5-HT1a) receptor partial agonist
HTR1APhase 2Spinal Cord InjuriesApr 2027
Memorial Sloan Kettering Cancer CenterFlibanserin
Serotonin 1A receptor agonist, serotonin 2A receptor antagonist, and serotonin reuptake in
HTR1A, HTR2A, SLC6A4Phase 2Breast CancerOct 2027
Yale UniversityDimethyltryptamine (DMT)
Serotonin 5-HT receptor agonist; endogenous psychedelic compound
HTR1A, HTR1B, HTR1D, HTR2APhase 1Major Depressive Disorder; Alcohol Use Disorder (AUD)Dec 2026
Joshua A. Lile, Ph.D.Cobenfy
M1 muscarinic receptor agonist and 5-HT1A receptor partial agonist
HTR1A, CHRM1Phase 1Cocaine Use Disorder (CUD)Jun 2032
Sichuan Kelun PharmaceuticalBrexpiprazole
Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist
DRD2, HTR1A, HTR2APhase 1Schizophrenia Disorders; Major Depressive Disorder; Bipolar Depression; Alcohol Use Disorder–
University Hospital, Basel, SwitzerlandDMT
5-HT receptor agonist, primarily 5-HT1A and 5-HT7
HTR1A, HTR1B, HTR1D, HTR5A, HTR7Phase 1Healthy–
University Hospital, Basel, SwitzerlandLSD
5-HT receptor agonist, primarily 5-HT1A and 5-HT7
HTR1A, HTR1B, HTR1D, HTR5A, HTR7Phase 1Healthy–

Conditions

Generalized Anxiety Disorder (3) Major Depressive Disorder (3) Depression (2) Healthy (2) Schizophrenia (1) Anxiety (1) Breast Cancer (1) Major Depressive Disorder (MDD) (1) Schizophrenia Disorders (1) Bipolar Depression (1) Alcohol Use Disorder (1) Spinocerebellar Ataxias (1)

Modalities

small molecule (18), protein or peptide (1)

Companies

Otsuka (2) Massachusetts General Hospital (2) University Hospital, Basel, Switzerland (2) Memorial Sloan Kettering Cancer Center (1) Vanda Pharmaceuticals (1) Sichuan Kelun Pharmaceutical (1) University of California, Los Angeles (1) VA Office of Research and Development (1) Northwell Health (1) University of Maryland, Baltimore (1) Takeda (1) Shanghai Mental Health Center (1) Yale University (1) Joshua A. Lile, Ph.D. (1) Spaulding Rehabilitation Hospital (1) Valenta Pharm JSC (1)

Related targets

HTR2A (7) DRD2 (5) HTR1B (3) HTR1D (3) SLC6A4 (2) HTR5A (2) HTR7 (2) TAAR1 (1) GABRA1 (1) GABRB2 (1) GABRG2 (1) GABRB3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.